ERBB2 and breast carcinoma: Recently, HER2-low breast cancers, defined by HER2 scores 1+ or 2+ without HER2/neu gene amplification, have come into clinical focus due to the marked therapeutic efficiency of trastuzumab deruxtecan (DS-8201) in metastatic, HER2-low breast cancers [7].